INBX רווח למניה בשנים עשר החודשים האחרונים Inhibrx Corp

Inhibrx Biosciences (INBX) relies on outsourced development and manufacturing, which drives the net income per share dynamics over the last four quarters. The value -8.98 serves as the current mark for this metric. Market capitalization is based on the sale of therapies for rare diseases, while growth potential is supported by a robust R&D pipeline of innovative protein candidates in the field of oncology.

Net income per share over 12 months measures the actual earnings attributable to a single share after accounting for all expenses and the volume of issuance, determining the business's fundamental margin of safety. Analyzing the earnings per share trend over the last four quarters allows for an assessment of Inhibrx Biosciences (INBX) resilience against colossal R&D expenditures and FDA clinical trial risks.